title: Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3.
abstract: Human THP-1 leukemia cells differentiate along the monocytic lineage following exposure to phorbol-12-myristate-13-acetate (PMA) or 1,25-dihydroxyvitamin D3 (VD3). In the monocytic cell line THP-1, PMA treatment resulted in a more differentiated phenotype than VD3, according to adherence, loss of proliferation, phagocytosis of latex beads, and expression of CD11b and CD14. Both differentiating substances induced similar effects in the release of superoxide anions (O2-). VD3-differentiated cells did not release prostaglandin E2 (PGE2), in contrast to PMA-differentiated cells, and in PMA-differentiated cells phospholipase A2 (PLA2) activity and expression was increase. Lipopolysaccharide (LPS)-stimulated tumor necrosis factor-alpha (TNF-alpha) release was higher in PMA-treated cells. PMA- but not VD3-differentiation resulted in a translocation of protein kinase C (PKC) isoenzymes to membrane fractions. Both differentiating agents up-regulated the expression of PKC isoenzymes. Whereas VD3 elevated mainly the expression of PKC-beta, PMA caused a strong increase in PKC-delta and a weak increase in PKC-alpha, PKC-epsilon, and PKC-zeta expression. These results indicate that phorbol ester and the active metabolite of vitamin D induce different signal pathways, which might result in different achievement of differentiation.
authors.affiliation: Biochemisches Institut, Klinik für Tumorbiologie, Freiburg, Federal Republic of Germany.
authors.forename: H
authors.initials: H
authors.lastname: Schwende
authors.forename: E
authors.initials: E
authors.lastname: Fitzke
authors.forename: P
authors.initials: P
authors.lastname: Ambs
authors.forename: P
authors.initials: P
authors.lastname: Dieter
mesh_terms: D015153:Blotting, Western; D002117:Calcitriol / Q000494:pharmacology*; D002273:Carcinogens / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003600:Cytosol / Q000201:enzymology; D015232:Dinoprostone / Q000378:metabolism; D004789:Enzyme Activation; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D007948:Leukemia, Monocytic, Acute / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology*; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis; D016177:Macrophage-1 Antigen / Q000096:biosynthesis; D010587:Phagocytosis / Q000187:drug effects; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D011493:Protein Kinase C / Q000378:metabolism; D013481:Superoxides / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D002273:Carcinogens; D007527:Isoenzymes; D018950:Lipopolysaccharide Receptors; D016177:Macrophage-1 Antigen; D014409:Tumor Necrosis Factor-alpha; D013481:Superoxides; D011493:Protein Kinase C; D010741:Phospholipases A; D054467:Phospholipases A2; D002117:Calcitriol; D015232:Dinoprostone; D013755:Tetradecanoylphorbol Acetate